Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion

The aim of this investigation was to study the expression of caspases 3, 6 and 8 and their association to apoptosis in preneoplastic and neoplastic lesions of the breast. The material consisted of nine benign breast epithelial hyperplasias, 15 atypical hyperplasias, 74 in situ and 82 invasive carcinomas. The extent of apoptosis was assessed by the TUNEL method and caspase 3, 6 and 8 expression by immunohistochemistry with specific antibodies. Increased caspase 3 immunopositivity, as compared to staining of normal breast ductal epithelium, was seen in 22% of benign epithelial hyperplasias, 25% of atypical hyperplasias, 58% of in situ carcinomas and 90% of invasive carcinomas. The corresponding percentages for caspase 6 and 8 were 11%, 25%, 60%, 87% and 22%, 57%, 84%, 83% respectively. In high-grade in situ lesions there were significantly more cases with strong caspase 3, 6 and 8 immunoreactivity than in low- and intermediate-grade lesions (P = 0.0045, P = 0.049 and P = 0.0001 respectively). In invasive carcinomas, however, no association between a high tumour grade and caspase 3, 6 or 8 expression was found (P = 0.27, P = 0.26 and P = 0.69 respectively). The mean apoptotic index was 0.14 ± 0.14% in benign epithelial hyperplasias, 0.17 ± 0.12% in atypical hyperplasias, 0.61 ± 0.88% in in situ carcinomas and 0.94 ± 1.21% in invasive carcinomas. In all cases strong caspase 3, 6 and 8 positivity was significantly associated with the extent of apoptosis (P < 0.001, P = 0.015 and P = 0.050 respectively). The results show that synthesis of caspases 3, 6 and 8 is up-regulated in neoplastic breast epithelial cells in parallel to the increase in the apoptotic index and progression of the breast lesions.

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[2]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[3]  O. Kallioniemi,et al.  Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry , 1990, Cancer.

[4]  B. Chaudhuri,et al.  Release of cytochrome c and decrease of cytochrome c oxidase in Bax‐expressing yeast cells, and prevention of these effects by coexpression of Bcl‐xL , 1997, FEBS letters.

[5]  A. Levine,et al.  Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis* , 1997, The Journal of Biological Chemistry.

[6]  R. Gascoyne,et al.  Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. , 1997, Blood.

[7]  G. Salvesen,et al.  Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis , 1997, The Journal of cell biology.

[8]  Y. Soini,et al.  The extent of apoptosis is inversely associated with bcl‐2 expression in premalignant and malignant breast lesions , 1997, Histopathology.

[9]  Sharad Kumar,et al.  Functional Activation of Nedd2/ICH-1 (Caspase-2) Is an Early Process in Apoptosis* , 1997, The Journal of Biological Chemistry.

[10]  R. Gascoyne,et al.  Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. , 1997, Cancer research.

[11]  Y. Soini,et al.  Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. , 1995, Cancer research.

[12]  F. O'Malley,et al.  Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. , 1997, Human pathology.

[13]  Thomas T. Y. Wang,et al.  Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. , 1995, Cancer research.

[14]  Andy J. Minn,et al.  Bcl-xL forms an ion channel in synthetic lipid membranes , 1997, Nature.

[15]  T. Tsuruo,et al.  Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis. , 1998, Biochemical and biophysical research communications.

[16]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[17]  Yuri Lazebnik,et al.  Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells , 1997, The EMBO journal.

[18]  W. Earnshaw,et al.  Activation of Multiple Interleukin-1β Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[19]  G. Gores,et al.  The role of proteases during apoptosis , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[21]  Fatteneh Ed. Tavassoli,et al.  Pathology of The Breast , 1992 .

[22]  G. Evan,et al.  A License to Kill , 1996, Cell.

[23]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[24]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[25]  P. Griffin,et al.  Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. , 1994, Biochemistry.

[26]  Seamus J. Martin,et al.  Degradation of Retinoblastoma Protein in Tumor Necrosis Factor- and CD95-induced Cell Death* , 1997, The Journal of Biological Chemistry.

[27]  Joe Rodriguez,et al.  Dismantling Cell–Cell Contacts during Apoptosis Is Coupled to a Caspase-dependent Proteolytic Cleavage of β-Catenin , 1997, The Journal of cell biology.

[28]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[29]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[30]  E. Solary,et al.  Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis , 1998, Oncogene.

[31]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[32]  W. Dupont,et al.  p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[33]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[34]  S. Schnitt,et al.  Estrogen receptor immunohistoohemistry in carcinoma in situ of the breast , 2010, Cancer.

[35]  J. Hendriks,et al.  Extent, distribution, and mammographic/ histological correlations of breast ductal carcinoma in situ , 1990, The Lancet.

[36]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[37]  Y. Soini,et al.  Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. , 1996, British Journal of Cancer.

[38]  R. Gascoyne,et al.  Immunohistochemical analysis of interleukin-1β-converting enzyme/ced-3 family protease, CPP32/Yama/caspase-3, in Hodgkin's disease , 1997 .

[39]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[40]  E. White,et al.  Lamin proteolysis facilitates nuclear events during apoptosis , 1996, The Journal of cell biology.

[41]  John Calvin Reed,et al.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. , 1994, The American journal of pathology.

[42]  V. Kosma,et al.  Apoptosis in breast cancer as related to histopathological characteristics and prognosis. , 1994, European journal of cancer.

[43]  Alan G. Porter,et al.  Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[44]  R. Gascoyne,et al.  Immunolocalization of the ICE/Ced-3–Family Protease, CPP32 (Caspase-3), in Non-Hodgkin's Lymphomas, Chronic Lymphocytic Leukemias, and Reactive Lymph Nodes , 1997 .

[45]  W. Fiers,et al.  Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal , 1997, FEBS letters.

[46]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[47]  G. Kroemer.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[48]  S. Masood,et al.  Potential value of hormone receptor assay in carcinoma in situ of breast. , 1990, American journal of clinical pathology.

[49]  Y. Soini,et al.  Histopathological evaluation of apoptosis in cancer. , 1998, The American journal of pathology.

[50]  D G Kirsch,et al.  Modulation of cell death by Bcl-XL through caspase interaction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Y. Soini,et al.  Apoptotic index and apoptosis influencing proteins bcl‐2, mcl‐1, bax and caspases 3, 6 and 8 in pancreatic carcinoma , 1998, Histopathology.